Dąbrowski Janusz M, Arnaut Luis G
Faculty of Chemistry, Jagiellonian University, Ingardena 3, 30-060 Kraków, Poland.
Photochem Photobiol Sci. 2015 Oct;14(10):1765-80. doi: 10.1039/c5pp00132c.
Photodynamic therapy (PDT) requires a medical device, a photosensitizing drug and adequate use of both to trigger biological mechanisms that can rapidly destroy the primary tumour and provide long-lasting protection against metastasis. We present a multidisciplinary view of the issues raised by the development of PDT. We show how spectroscopy, photophysics, photochemistry and pharmacokinetics of photosensitizers determine the mechanism of cell death and clinical protocols. Various examples of combinations with chemotherapies and immunotherapies illustrate the opportunities to potentiate the outcome of PDT. Particular emphasis is given to the mechanisms that can be exploited to establish PDT as a systemic treatment of solid tumours and metastatic disease.
光动力疗法(PDT)需要一种医疗设备、一种光敏药物以及对两者的充分利用,以触发能够迅速破坏原发性肿瘤并提供长期抗转移保护的生物学机制。我们对光动力疗法发展所引发的问题进行了多学科视角的探讨。我们展示了光敏剂的光谱学、光物理学、光化学和药代动力学如何决定细胞死亡机制和临床方案。与化疗和免疫疗法联合使用的各种实例说明了增强光动力疗法疗效的机会。特别强调了可用于将光动力疗法确立为实体肿瘤和转移性疾病全身治疗方法的机制。